

Normal P axis, PR, rate & rhythm
P V1 - .10 mV or more negative
Q/Tc in V1 & V2
ST-T negative ANT/LAT/INF
T > -.30 mV, ST > -.05 mV

GlobalData»
MediPoint

**PROSTHETIC HEART VALVES —
GLOBAL ANALYSIS AND MARKET FORECASTS**

Executive Summary

Key Metrics in Major Markets

Prosthetic Heart Valves, Key Metrics in Major Markets	
(2013) Global Sales Volume	386,464
(2013) Global Market Value (\$m)	\$2,082.4m
(2013) US Market Value (\$m)	\$762.8m
(2013) 5EU Market Value (\$m)	\$882.4m
(2013) Asia-Pacific Market Value (\$m)	\$404.5m
(2013) Brazil Market Value (\$m)	\$32.6m
Key Events	
(2013) Edwards Lifesciences receives regulatory approval to market Sapien XT in Japan	
(2014) Strong pipeline of transcatheter aortic valve replacement devices that are fully repositionable and retrievable	
Forecast	
(2020) Global Sales Volume	592,257
(2020) Global Market Value (\$m)	\$4,455.1m
(2020) US Market Value (\$m)	\$1,527m
(2020) 5EU Market Value	\$2,319m
(2020) Asia-Pacific Market Value (\$m)	\$560.6m
(2020) Brazil Market Value (\$m)	\$48.4m
Source: GlobalData, primary research interviews with leading cardiac surgeons and interventional cardiologists in 10 markets (US, France, Germany, Italy, Spain, UK, Japan, China, India, and Brazil)	
5EU = France, Germany, Italy, Spain, and the UK; Asia-Pacific = Japan, China, and India	


The global prosthetic heart valve market in 2013 is estimated to be valued at \$2,082m across the 10 major markets covered in this report, which includes the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, India, China, and Brazil.

By the end of the forecast period in 2020, the global prosthetic heart valve market will grow to approximately \$4,455m at a Compound Annual Growth Rate (CAGR) of 11.4%.

The key drivers for the market in the forecast are:

- The growing prevalence of valvular heart disease and an aging population around the globe
- Technological advancements in the field of interventional cardiology that include transcatheter aortic valve replacement (TAVR) and the desire to eliminate the need for open surgical procedures for valve replacements
- The development of TAVR devices that are fully repositionable and retrievable, providing better clinical outcomes and reducing complications associated with valve replacement procedures

Executive Summary



The US market accounts for the largest segment of the prosthetic heart valve market. While China owns a significant portion of the market in 2013, its share is expected to decrease in the forecast period due to the emergence of TAVR, which is expected to experience rapid growth and is not yet approved in China. The 5EU countries (France, Germany, Italy, Spain, and the UK) are technologically the most advanced market, with the

best availability of TAVR devices. The emerging markets see the most open surgical procedures and are restricted due to the high cost of minimally invasive procedures. As training programs for surgeons and product prices reduce, the emerging markets present a strong market opportunity for additional revenue for manufacturers. The growing need for multinational companies will be to better target the fast-growing markets and continue to be a leader in development to combat the threat of rising local manufacturers.

Technological Trends

While heart valve replacement has been around for decades, minimally invasive techniques have only come into the picture recently. Modern heart valve replacements show increased durability, improved conformance to native tissue, and improved hemodynamics over older models. Advancements in diagnostic imaging have also streamlined the valve replacement process by allowing the physician to visualize the diseased valve and appropriately size the prosthetic. These imaging techniques represent an opportunity for prosthetic heart valve manufacturers to continue training programs for early detection of asymptomatic valve disease.

The technological developments in this space will continue to result in positive market growth. The primary technological drivers for TAVR devices include the development of low-profile, repositionable, and retrievable systems. Low-profile devices are of particular interest in the Asian

Executive Summary

market, where patient arteries are smaller in diameter. Generally, there remains room for improvement in the efficacy of TAVR devices, and as the products evolve, there will be continued growth in this market.

Key Players in the Prosthetic Heart Valve Market

Currently, the prosthetic heart valve market is dominated by two players: Edwards Lifesciences and Medtronic. Medtronic has a strong presence in all three segments of this market (mechanical, tissue, and transcatheter), while Edwards has built a trusted brand in tissue valves and TAVR. In terms of transcatheter valves, these companies have launched products that are considered the gold standard in the market, and continue to innovate within this space. Direct Flow Medical and Boston Scientific are currently developing the next-generation in TAVR systems, along with the top two players, and early data from their devices have been very positive. St. Jude Medical and Sorin Group are the two big players in the surgical valve market segments (mechanical and tissue). St. Jude Medical currently manufactures what is considered the gold standard in mechanical valves, and also has a line of tissue valve products as well.

Prosthetic Heart Valve Market Future Outlook

The growth of the prosthetic heart valve market will be driven primarily by the adoption of TAVR around the globe. While surgical valves will continue to have a presence in the market, they

are not expected to see rapid growth in any of the regions. Despite the high product price of TAVR, physicians recognize the clinical benefits of a minimally invasive procedure as opposed to open surgery. As physician education improves and they have access to more robust clinical data, the outlook for the TAVR market looks strong, with much room for further product improvement in next-generation devices.

The global market is expected to grow at a CAGR of 11.4%. The fastest growing markets will be Germany, Italy, and France, at CAGRs of 16.6%, 13.5%, and 12.5%, respectively. This is because a much greater number of TAVR devices are approved in the major European markets as opposed to others. The slowest growth will be seen in Brazil, India, and China, with CAGRs of 5.7%, 5.2%, and 3.3%, respectively. This is because high device cost restricts patient access to TAVR in Brazil and India, while China has not yet approved the procedure at all.

The market outlook for prosthetic heart valves looks strong in Western markets, as there is still much room for product adoption and growth. Regionally, one can expect slightly different drivers for growth. In the Western markets, availability of TAVR devices is expected to drive growth. In the Asia-Pacific (APAC) countries, lower costing devices will allow for more widespread adoption. In Japan in particular, low-profile devices will allow manufacturers to access a larger subset of patients.

Executive Summary

What Do Physicians Think?

Physicians assert that the future of TAVR is bright due to positive clinical outcomes:

“I have a conflict of interest because I do the procedure, of course, but the outlook is very positive, clearly. The results are very positive. The discussion now is: where do the indications stop?”

Key Opinion Leader

“The market opportunity is going to be to let most referring physicians and general internists and cardiologists know that there’s a whole world out there that they can offer their patients that will both improve their symptoms and lengthen their lives.”

Key Opinion Leader

High procedure and device cost is the primary barrier to adoption of TAVR in emerging markets:

“The costing is important in the US... and the costing will be important here also. There has to be a practical and pragmatic approach to that. It should not be too expensive.”

Key Opinion Leader

There is an increasing patient preference for bioprosthetic valves over mechanical valves:

“We don’t see many patients under the age of 15 needing valve surgery, but when we do, we have to emphasize to them that it probably is in their best overall long-term interest to have the mechanical valve, but sometimes that takes some persuading.”

Key Opinion Leader

Physicians mention unmet needs in the transcatheter valve space:

“...we thought the issue of severe aortic stenosis is solved if the patient has a new valve. And if he is still suffering from moderate paravalvular aortic regurgitation that will not be an issue for the patient. But actually, we were not right, and many of these patients did not really come out very well out of the procedure.”

Key Opinion Leader

“I think the only uncertainties are... the durability question, because we simply don’t have the data. I think we need to solve the Pacemaker issue, particularly in some of the device[s]... and we need to work out how we’re going to deliver... to match the demand.”

Key Opinion Leader

Executive Summary

“...we need to learn from the TAVR story and get busy in the mitral valve as well. That’s the next major area for development, in my opinion... there’s an opportunity waiting to be filled by somebody who can work out the easiest and safest way to put devices into the mitral position.”

Key Opinion Leader

SAMPLE

Table of Contents

1 Table of Contents

1	Table of Contents	7
1.1	List of Tables	15
1.2	List of Figures	21
2	Introduction	24
2.1	Anatomy.....	24
2.2	Epidemiology	24
2.3	Related Reports	25
3	Industry Overview	26
3.1	Overview.....	26
3.1.1	Mechanical Heart Valves.....	26
3.1.2	Tissue Heart Valves	28
3.1.3	Transcatheter Heart Valves.....	29
3.2	Indications.....	30
3.2.1	Valvular Stenosis	30
3.2.2	Valvular Regurgitation	31
3.3	Clinical Presentation	31
3.3.1	Diagnosis	31
3.3.2	Risk Assessment Tools	31
3.4	Clinical Outcomes	33
3.4.1	Treatment Options.....	33
3.4.2	Life Style Changes	34

Table of Contents

3.4.3	Complications.....	34
3.5	Applications of Technology	35
3.6	Market Access	35
3.6.1	Purchasing Decisions.....	35
3.7	Influence of Clinical Trials	35
3.8	Brand Loyalty.....	35
3.9	Adoption.....	36
3.10	Regulation.....	37
3.10.1	US.....	37
3.10.2	5EU.....	38
3.10.3	APAC.....	39
3.10.4	South America.....	42
3.11	Reimbursement.....	43
3.11.1	US.....	43
3.11.2	5EU.....	45
3.11.3	APAC.....	49
3.11.4	South America.....	52
3.12	Procedure Trends	53
3.12.1	Global Overview.....	53
3.12.2	By Country	54
3.13	Regulatory Issues/Recalls.....	75
3.13.1	Portico TAVR Implants Halted Due to Safety Concerns	75
3.14	M&A, Key Partnerships.....	75

Table of Contents

3.14.1	Licensing Agreement Between Symetis and Endoluminal Sciences.....	75
3.14.2	Manufacturing Agreement Between Sorin Group and Boston Scientific.....	75
3.15	Economic Impact	75
3.15.1	Indirect Costs	75
3.15.2	Direct Costs	77
4	Unmet Needs.....	78
4.1	Delivery & Implantation	78
4.1.1	Mechanism of Deployment.....	78
4.1.2	Anchoring.....	78
4.1.3	Retrievability.....	79
4.1.4	Repositionability	79
4.1.5	Artery Accessibility	79
4.1.6	Rapid Pacing.....	80
4.1.7	Coronary Ostia Occlusion.....	81
4.1.8	Motorized Delivery Systems.....	81
4.2	Performance	82
4.2.1	Durability	82
4.2.2	Thrombogenicity.....	83
4.2.3	Effective Orifice Area.....	83
4.2.4	Coefficient of Friction.....	83
4.3	Crimping	84
4.4	Stenting.....	84
4.5	Replaceable Leaflets.....	84

Table of Contents

4.6	Emboic Protection	85
4.7	Pacemaker Placement	85
5	Market Opportunity Analysis	87
5.1	Overview	87
5.2	Emerging Markets for TAVR	87
5.3	Increasing Tissue Valve Lifespan	88
5.4	Valve-in-Valve Procedures (Re-replacement)	89
5.5	Transcatheter Mitral Valve Replacement	90
5.6	Balloon Valvuloplasty	91
6	Market Drivers and Barriers	92
6.1	Driver: Rising Disease Prevalence	92
6.2	Driver: Multimodality Imaging	93
6.3	Driver: Alternative Access Routes	94
6.4	Driver: Lower Risk Patient Access	94
6.5	Driver: Patient Demand and Awareness	95
6.6	Driver: Advanced Computational Tools	96
6.7	Driver: Rising Competition and Innovation	96
6.8	Barrier: High Device and Procedure Cost	97
6.9	Barrier: Burden of Rising Regulation	97
6.10	Barrier: Medical Device Excise Tax	98
6.11	Barrier: Proving Long-Term Efficacy	98
6.12	Substitute: Valve Repair	99
6.13	Substitute: Balloon Valvuloplasty	99

Table of Contents

7	Competitive Assessment	100
7.1	Overview.....	100
7.2	Classification Based on Features	100
7.2.1	Mechanical Heart Valves.....	100
7.2.2	Tissue Heart Valves	103
7.2.3	Transcatheter Heart Valves.....	106
7.3	Market Dynamics Analysis	107
7.4	Product Profiles.....	109
7.4.1	Mechanical Heart Valves.....	109
7.4.2	Tissue Heart Valves	115
7.4.3	Transcatheter Heart Valves.....	121
8	Pipeline Assessment.....	135
8.1	Overview.....	135
8.2	Product Profiles.....	135
8.2.1	Cytograft Tissue Valve (Cytograft Tissue Engineering)	135
8.2.2	Centera Valve (Edwards Lifesciences).....	136
8.2.3	Colibri Heart Valve (Colibri Heart Valve).....	137
8.2.4	Cormove (Perouse Medical).....	138
8.2.5	Endo valve (Micro Interventional Devices).....	139
8.2.6	HLT Transcatheter Valve System (Heart Leaflet Technology)	140
8.2.7	Kalangos Valve (Leman Cardiovascular).....	141
8.2.8	Tiara Valve (Neovasc).....	142
8.2.9	Trinity Valve (Transcatheter Technologies GmbH)	143

Table of Contents

8.2.10	Vanguard Exchangeable Heart Valve System (ValveXchange).....	144
9	Clinical Trials to Watch	146
9.1	Overview.....	146
9.2	CoreValve Evolut R (Medtronic).....	146
9.3	TRANSFORM Trial — Intuity Valve System (Edwards Lifesciences)	146
9.4	PROACT Trial — On-X Plus 1.5 Mechanical Heart Valve (On-X Life Technologies)	147
9.5	PARTNER II Trial — Sapien XT (Edwards Lifesciences)	147
9.6	PARTNER III Trial — Sapien 3 (Edwards Lifesciences).....	147
9.7	REPRISE III IDE/PMA Trial — Lotus Valve System (Boston Scientific).....	148
9.8	SENTINEL-H Trial — Sentinel Cerebral Protection System (Claret Medical)	148
10	Current and Future Players.....	149
10.1	Overview.....	149
10.2	Trends in Corporate Strategy.....	149
10.3	Company Profiles.....	150
10.3.1	AorTech International.....	150
10.3.2	Boston Scientific.....	152
10.3.3	Braile Biomédica	153
10.3.4	CardiAQ Valve Technologies	154
10.3.5	Claret Medical	155
10.3.6	Colibri Heart Valve	156
10.3.7	Cytograft Tissue Engineering	157
10.3.8	Direct Flow Medical.....	158
10.3.9	Edwards Lifesciences.....	159

Table of Contents

10.3.10 Heart Leaflet Technologies.....	161
10.3.11 JenaValve Technology	162
10.3.12 Lemman Cardiovascular	163
10.3.13 Micro Interventional Devices	164
10.3.14 Neovasc.....	165
10.3.15 On-X Life Technologies, Inc.	166
10.3.16 Perouse Medical	167
10.3.17 Sorin Group.....	168
10.3.18 St. Jude Medical.....	169
10.3.19 Symetis	171
10.3.20 Transcatheter Technologies GmbH.....	172
10.3.21 TTK Healthcare	173
10.3.22 ValveXchange	174
11 Strategic Competitive Assessment.....	176
11.1 Company Market Share	176
11.1.1 Global Overview.....	176
11.1.2 By Region	177
11.1.3 By Country	179
12 Market Outlooks by Market Segment.....	187
12.1 Market Segment Share	187
12.1.1 Global.....	187
12.1.2 By Region	188
13 Market Outlooks by Geography	192

Table of Contents

13.1	Global Overview.....	192
13.2	US.....	196
13.3	France	199
13.4	Germany	203
13.5	Italy	207
13.6	Spain	211
13.7	UK.....	214
13.8	Japan.....	218
13.9	China	222
13.10	India.....	226
13.11	Brazil.....	230
14	Appendix.....	234
14.1	Bibliography	234
14.2	Abbreviations	245
14.3	Report Methodology.....	248
14.3.1	Overview	248
14.3.2	Coverage	248
14.3.3	Secondary Research.....	248
14.4	Forecasting Methodology.....	250
14.5	Physicians and Specialists Included in This Study	251
14.6	About the Authors	252
14.6.1	Analysts	252
14.6.2	Global Head of Healthcare	253

Table of Contents

14.7	About GlobalData.....	254
14.8	Disclaimer	254
1.1	List of Tables	
Table 1:	Overview of Symptoms, Risk Factors, and Treatments.....	26
Table 2:	Evolution of the Mechanical Heart Valve.....	27
Table 3:	Evolution of the Tissue Heart Valve.....	29
Table 4:	Comparison of Surgical and Transcatheter Procedures.....	30
Table 5:	NYHA Functional Classification of Cardiac Disease Patients.....	32
Table 6:	Drug Treatment Paradigm for Aortic Valve Disease.....	33
Table 7:	Regulatory Differences Between the US and EU.....	38
Table 8:	Medicare National Average of Inpatient Hospital Reimbursement for Valve Replacement, 2014–2015.....	44
Table 9:	ICD-9 Coding Guide for Valvular Heart Disease, 2014.....	45
Table 10:	Forecast Indirect National Costs For Aortic Valve Disease in the US (\$bn), 2011–2020.....	76
Table 11:	Forecast Indirect National Costs For Aortic Valve Disease in the EU (\$bn), 2011–2020.....	76
Table 12:	Minimum Arterial Diameter Required for TAVR Systems.....	80
Table 13:	Global Projected Prevalence of Aortic Stenosis, 2013–2020.....	92
Table 14:	Current Access Routes for Transcatheter Aortic Valve Replacement.....	94
Table 15:	Mechanical Heart Valves, SWOT Analysis, 2014.....	101
Table 16:	Marketed Mechanical Heart Valve Products, 2014.....	102
Table 17:	Tissue Heart Valves, SWOT Analysis, 2014.....	104
Table 18:	Marketed Tissue Heart Valve Products, 2014.....	105
Table 19:	Transcatheter Heart Valves, SWOT Analysis, 2014.....	106

Table of Contents

Table 20: Marketed Transcatheter Heart Valve Products, 2014 107

Table 21: Product Profile — Carbomedics Standard Aortic Mechanical Valve (Sorin Group)..... 109

Table 22: Carbomedics Standard Aortic Mechanical Valve, SWOT Analysis, 2014 110

Table 23: Product Profile — Open Pivot Mechanical Valve (Medtronic) 111

Table 24: Open Pivot Mechanical Valve, SWOT Analysis, 2014 111

Table 25: Product Profile — On-X Mechanical Heart Valve (On-X Life Technologies)..... 112

Table 26: On-X Mechanical Heart Valve, SWOT Analysis, 2014..... 113

Table 27: Product Profile — On-X Plus 1.5 Mechanical Heart Valve (On-X Life Technologies) 113

Table 28: On-X Plus 1.5 Mechanical Heart Valve, SWOT Analysis, 2014 114

Table 29: Product Profile — Regent Valve (St. Jude Medical) 114

Table 30: Regent Valve, SWOT Analysis, 2014..... 115

Table 31: Product Profile — Carpentier-Edwards Perimount Pericardial Valve (Edwards Lifesciences)..... 116

Table 32: Carpentier-Edwards Perimount Pericardial Valve, SWOT Analysis, 2014..... 116

Table 33: Product Profile — 3f Enable Sutureless Aortic Bioprosthesis (Medtronic)..... 117

Table 34: 3f Enable Sutureless Aortic Bioprosthesis, SWOT Analysis, 2014..... 117

Table 35: Product Profile — Hancock II (Medtronic) 118

Table 36: Medtronic Hancock II, SWOT Analysis, 2014..... 118

Table 37: Product Profile — Mitroflow Aortic Pericardial Heart Valve (Sorin Group)..... 119

Table 38: Sorin Group Mitroflow Aortic Pericardial Heart Valve, SWOT Analysis, 2014..... 119

Table 39: Product Profile — Trifecta Heart Valve (St. Jude Medical)..... 120

Table 40: St. Jude Medical Trifecta Heart Valve, SWOT Analysis, 2014 121

Table 41: Product Profile — Acurate TA/Acurate neo (Symetis) 121

Table 42: Acurate TA/Acurate neo, SWOT Analysis, 2014 122

Table 43: Product Profile — Lotus Valve System (Boston Scientific) 123

Table of Contents

Table 44: Boston Scientific Lotus Valve System, SWOT Analysis, 2014 124

Table 45: Product Profile — Direct Flow Medical Transcatheter Valve (Direct Flow Medical) 125

Table 46: Direct Flow Medical Valve, SWOT Analysis, 2014 125

Table 47: Product Profile — Sapien XT Valve (Edwards Lifesciences) 126

Table 48: Sapien XT Valve, SWOT Analysis, 2014..... 127

Table 49: Product Profile — JenaValve (JenaValve Technology)..... 128

Table 50: JenaValve, SWOT Analysis, 2014 128

Table 51: Product Profile — CoreValve (Medtronic) 129

Table 52: CoreValve, SWOT Analysis, 2014 130

Table 53: Product Profile — CoreValve Evolut R (Medtronic) 131

Table 54: CoreValve Evolut R, SWOT Analysis, 2014 131

Table 55: Product Profile — Portico Valve (St. Jude Medical)..... 132

Table 56: Portico Valve, SWOT Analysis, 2014 132

Table 57: Product Profile — Inovare Valve (Braile Biomédica)..... 133

Table 58: Inovare Valve, SWOT Analysis, 2014 134

Table 59: Product Profile — Cytograft Tissue Valve (Cytograft Tissue Engineering) 135

Table 60: Cytograft Tissue Valve, SWOT Analysis, 2014 136

Table 61: Product Profile — Centera Valve (Edwards Lifesciences Corporation) 136

Table 62: Centera Valve, SWOT Analysis, 2014 137

Table 63: Product Profile — Colibri Heart Valve (Colibri Heart Valve)..... 138

Table 64: Colibri Heart Valve, SWOT Analysis, 2014 138

Table 65: Product Profile — Cormove (Perouse Medical)..... 139

Table 66: Cormove, SWOT Analysis, 2014 139

Table 67: Product Profile — Endo valve (Micro Interventional Devices) 140

Table of Contents

Table 68: Endo Valve, SWOT Analysis, 2014 140

Table 69: Product Profile — HLT Transcatheter Valve System (Heart Leaflet Technology)..... 141

Table 70: HLT Transcatheter Valve System, SWOT Analysis, 2014 141

Table 71: Product Profile — Kalangos Valve (Leman Cardiovascular)..... 142

Table 72: Kalangos Valve, SWOT Analysis, 2014 142

Table 73: Product Profile — Tiara Valve (Neovasc.)..... 142

Table 74: Tiara Valve, SWOT Analysis, 2014..... 143

Table 75: Product Profile — Trinity Valve (Transcatheter Technologies GmbH)..... 143

Table 76: Trinity VALVE, SWOT Analysis, 2014..... 144

Table 77: Product Profile — Vanguard Exchangeable Heart Valve System (ValveXchange)..... 145

Table 78: Vanguard Exchangeable Heart Valve System, SWOT Analysis, 2014..... 145

Table 79: AorTech International plc, Company Profile, 2014 151

Table 80: AorTech International, SWOT Analysis, 2014 151

Table 81: Boston Scientific Corporation, Company Profile, 2014 152

Table 82: Boston Scientific Corporation, SWOT Analysis, 2014..... 153

Table 83: Braile Biomédica, Company Profile, 2014 154

Table 84: Braile Biomédica, SWOT Analysis, 2014 154

Table 85: CardiAQ Valve Technologies, Company Profile, 2014 155

Table 86: CardiAQ Valve Technologies, SWOT Analysis, 2014..... 155

Table 87: Claret Medical, Inc., Company Profile, 2014 156

Table 88: Claret Medical, SWOT Analysis, 2014 156

Table 89: Colibri Heart Valve, LLC, Company Profile, 2014..... 157

Table 90: Colibri Heart Valve, SWOT Analysis, 2014 157

Table 91: Cytograft Tissue Engineering, Inc., Company Profile, 2014..... 158

Table of Contents

Table 92: Cytograft Tissue Engineering, SWOT Analysis, 2014..... 158

Table 93: Direct Flow Medical, Inc., Company Profile, 2014 159

Table 94: Direct Flow Medical, SWOT Analysis, 2014 159

Table 95: Edwards Lifesciences Corporation, Company Profile, 2014 160

Table 96: Edwards Lifesciences, SWOT Analysis, 2014..... 161

Table 97: Heart Leaflet Technologies, Company Profile, 2014..... 161

Table 98: Heart Leaflet Technologies, SWOT Analysis, 2014..... 162

Table 99: JenaValve Technology, Company Profile, 2014 162

Table 100: JenaValve Technology, SWOT Analysis, 2014 163

Table 101: Lemnan Cardiovascular, Company Profile, 2014 163

Table 102: Lemnan Cardiovascular, SWOT Analysis, 2014..... 164

Table 103: Micro Interventional Devices, Inc., Company Profile, 2014 164

Table 104: Micro Interventional Devices, SWOT Analysis, 2014..... 165

Table 105: Neovasc, Inc., Company Profile, 2014 165

Table 106: Neovasc, SWOT Analysis, 2014..... 166

Table 107: On-X Life Technologies, Inc., Company Profile, 2014 166

Table 108: On-X Life Technologies, SWOT Analysis, 2014 167

Table 109: Perouse Medical, Company Profile, 2014 167

Table 110: Perouse Medical, SWOT Analysis, 2014..... 168

Table 111: Sorin Group, Company Profile, 2014 168

Table 112: Sorin Group, SWOT Analysis, 2014..... 169

Table 113: St. Jude Medical, Inc., Company Profile, 2014..... 170

Table 114: St. Jude Medical, Inc., SWOT Analysis, 2014 170

Table 115: Symetis, Company Profile, 2014..... 171

Table of Contents

Table 116: Symetis, SWOT Analysis, 2014 171

Table 117: Transcatheter Technologies GmbH, Company Profile, 2014 172

Table 118: Transcatheter Technologies, SWOT Analysis, 2014 172

Table 119: TTK Healthcare, Company Profile, 2014..... 173

Table 120: TTK Healthcare, SWOT Analysis, 2014 173

Table 121: ValveXchange, Inc., Company Profile, 2014 174

Table 122: ValveXchange, SWOT Analysis, 2014 175

Table 123: Global Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020 188

Table 124: 5EU Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020 ... 189

Table 125: APAC Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020. 191

Table 126: US Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020 197

Table 127: France Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020 200

Table 128: Germany Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020
..... 204

Table 129: Italy Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020.... 208

Table 130: Spain Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020 . 212

Table 131: UK Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020 215

Table 132: Japan Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020. 219

Table 133: China Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020. 223

Table 134: India Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020... 227

Table 135: Brazil Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020 . 231

Table of Contents

1.2 List of Figures

Figure 1: Hierarchy of Valvular Heart Disease 30

Figure 2: Operative Risk for Severe, Symptomatic Aortic Valve Disease Patients, 2009 37

Figure 3: US Procedure Volume Forecast by Market Segment, 2011–2020 55

Figure 4: US Procedure Volume Comparison by Market Segment, 2013 & 2020 56

Figure 5: France Procedure Volume Forecast by Market Segment, 2011–2020 57

Figure 6: France Procedure Volume Comparison by Market Segment, 2013 & 2020 58

Figure 7: Germany Procedure Volume Forecast by Market Segment, 2011–2020 59

Figure 8: Germany Procedure Volume Comparison by Market Segment, 2013 & 2020 60

Figure 9: Italy Procedure Volume Forecast by Market Segment, 2011–2020 61

Figure 10: Italy Procedure Volume Comparison by Market Segment, 2013 & 2020 62

Figure 11: Spain Procedure Volume Forecast by Market Segment, 2011–2020 63

Figure 12: Spain Procedure Volume Comparison by Market Segment, 2013 & 2020 64

Figure 13: UK Procedure Volume Forecast by Market Segment, 2011–2020 65

Figure 14: UK Procedure Volume Comparison by Market Segment, 2013 & 2020 66

Figure 15: Japan Procedure Volume Forecast by Market Segment, 2011–2020 67

Figure 16: Japan Procedure Volume Comparison by Market Segment, 2013 & 2020 68

Figure 17: China Procedure Volume Forecast by Market Segment, 2011–2020 69

Figure 18: China Procedure Volume Comparison by Market Segment, 2013 & 2020 70

Figure 19: India Procedure Volume Forecast by Market Segment, 2011–2020 71

Figure 20: India Procedure Volume Comparison by Market Segment, 2013 & 2020 72

Figure 21: Brazil Procedure Volume Forecast by Market Segment, 2011–2020 73

Figure 22: Brazil Procedure Volume Comparison by Market Segment, 2013 & 2020 74

Figure 23: Global Company Market Shares for Prosthetic Heart Valves, 2012 176

Table of Contents

Figure 24: EU Company Market Share for Prosthetic Heart Valves, 2012	178
Figure 25: APAC Company Market Shares for Prosthetic Heart Valves, 2012.....	179
Figure 26: US Company Market Shares for Prosthetic Heart Valves, 2012	180
Figure 27: France Company Market Shares for Prosthetic Heart Valves, 2012	180
Figure 28: Germany Company Market Shares for Prosthetic Heart Valves, 2012.....	181
Figure 29: Italy Company Market Shares for Prosthetic Heart Valves, 2012.....	182
Figure 30: Spain Company Market Shares for Prosthetic Heart Valves, 2012	182
Figure 31: UK Company Market Shares for Prosthetic Heart Valves, 2012	183
Figure 32: Japan Company Market Shares for Prosthetic Heart Valves, 2012.....	184
Figure 33: China Company Market Shares for Prosthetic Heart Valves, 2012.....	184
Figure 34: India Company Market Shares for Prosthetic Heart Valves, 2012	185
Figure 35: Brazil Company Market Shares for Prosthetic Heart Valves, 2012	186
Figure 36: Global Market Value Forecast by Market Segment for Prosthetic Heart Valves, \$m, 2011–2020	187
Figure 37: 5EU Market Value Forecast by Market Segment for Prosthetic Heart Valves, 2011–2020	189
Figure 38: APAC Market Value Forecast by Market Segment for Prosthetic Heart Valves, 2011–2020	190
Figure 39: Global Sales Volume for Prosthetic Heart Valves, Number of Units, 2011–2020	192
Figure 40: Global Market Value Forecast by Country, \$m, 2011–2020.....	193
Figure 41: Global Market Share Comparison by Country, 2013 & 2020	195
Figure 42: US Market Value Forecast by Market Segment, \$m, 2011–2020	196
Figure 43: US Market Value Comparison by Market Segment, 2013 & 2020.....	198
Figure 44: US Average Selling Price by Market Segment, 2011–2020	199
Figure 45: France Market Value Forecast by Market Segment, \$m, 2011–2020	200
Figure 46: France Market Value Comparison by Market Segment, 2013 & 2020.....	202
Figure 47: France Average Selling Price by Market Segment, 2011–2020	203

Table of Contents

Figure 48: Germany Market Value Forecast by Market Segment, \$m, 2011–2020204

Figure 49: Germany Market Value Comparison by Market Segment, 2013 & 2020206

Figure 50: Germany Average Selling Price by Market Segment, 2011–2020.....207

Figure 51: Italy Market Value Forecast by Market Segment, \$m, 2011–2020208

Figure 52: Italy Market Value Comparison by Market Segment, 2013 & 2020209

Figure 53: Italy Average Selling Price by Market Segment, 2011–2020210

Figure 54: Spain Market Value Forecast by Market Segment, \$m, 2011–2020211

Figure 55: Spain Market Value Comparison by Market Segment, 2013 & 2020.....213

Figure 56: Spain Average Selling Price by Market Segment, 2011–2020214

Figure 57: UK Market Value Forecast by Market Segment, \$m, 2011–2020215

Figure 58: UK Market Value Comparison By Market Segment, 2013 & 2020217

Figure 59: UK Average Selling Price by Market Segment, 2011–2020218

Figure 60: Japan Market Value Forecast by Market Segment, \$m, 2011–2020219

Figure 61: Japan Market Value Comparison by Market Segment, 2013 & 2020221

Figure 62: Japan Average Selling Price by Market Segment, 2011–2020222

Figure 63: China Market Value Forecast by Market Segment, \$m, 2011–2020223

Figure 64: China Market Value Comparison by Market Segment, 2013 & 2020225

Figure 65: China Average Selling Price by Market Segment, 2011–2020.....226

Figure 66: India Market Value Forecast by Market Segment, \$m, 2011–2020.....227

Figure 67: India Market Value Comparison by Market Segment, 2013 & 2020229

Figure 68: India Average Selling Price by Market Segment, 2011–2020230

Figure 69: Brazil Market Value Forecast by Market Segment, \$m, 2011–2020.....231

Figure 70: Brazil Market Value Comparison by Market Segment, 2013 & 2020.....232

Figure 71: Brazil Average Selling Price by Market Segment, 2011–2020233

Introduction

2 Introduction

2.1 Anatomy

Healthy heart valves ensure that blood flows in the proper direction at the appropriate time and with the appropriate pressure. The contraction and relaxation of the heart generates pressure differences that cause the valves to open and shut, allowing blood to fill the atria and ventricles at alternating times. The four valves in the heart are the aortic, mitral, pulmonic, and tricuspid valves. Note that the aortic, pulmonic and tricuspid valves consist of three leaflets each, while the mitral, or bicuspid, valve consists of two leaflets, anterior and posterior.

2.2 Epidemiology

Valvular heart disease (VHD) is characterized by damage to one of the four valves. The most commonly affected valves are the aortic valve, which controls blood flow between the aorta and the rest of the body, and the mitral valve, which controls blood flow between the atria and ventricles. Depending on the severity of damage, VHD can result in congestive heart failure (CHF) or other serious complications.

VHD can be treated via implantation of a prosthetic heart valve that mimics the function of a human heart valve, thus improving hemodynamics. These prostheses have a passive mode of functioning in that they open and close in response to pressure and flow changes within the heart. For the purposes of this report, the aortic and mitral valves are of primary concern because they are most commonly affected by this disorder.

Valve replacement, whether surgical or via transcatheter methods, has been shown to improve both patient morbidity and mortality outcomes. These days, surgeons utilize both open-heart as well as percutaneous valve replacement devices. However, while both the aortic and mitral valves are commonly replaced using open-heart techniques, transcatheter technology has thus far focused on the aortic valve; there are no transcatheter mitral valve replacement products on the market to date.

While the transcatheter mitral market segment is slowly growing, the majority of heart valve prosthesis global revenue is generated by three categories of devices: mechanical heart valves and tissue heart valves, which are both designed for open-heart replacement of the mitral or aortic valve, and transcatheter aortic valve replacement (TAVR). Mechanical valves are typically made

Valve replacement, whether surgical or via transcatheter methods, has been shown to improve both patient morbidity and mortality outcomes.

Introduction

from non-biological materials such as metals, while tissue valves originate from animals such as pigs. The implantation of both mechanical valves and bioprosthetic valves requires surgery, while TAVR is breaking new ground as a minimally invasive technique that improves patient comfort and recovery time.

2.3 Related Reports

- GlobalData (2014). Coronary Stents – Global Market Analysis and Forecasts, December 2014, GDME1119CFR
- GlobalData (2013). Drug Eluting Balloons – Global Market Analysis and Forecasts, September 2013, GDME0179MAR
- GlobalData (2013). Cardiac Assist Devices – Global Market Analysis and Forecasts, March 2013, GDME0175MAR
- GlobalData (2012). Bioabsorbable Stents – Global Market Analysis and Forecasts, December 2012, GDME0164MAR

Appendix

14.7 About GlobalData

GlobalData is a leading global provider of business intelligence in the Healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports and forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Japan, Singapore, and Australia.

14.8 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher, GlobalData.